Sinclair Pharma PLC (LON:SPH) had its target price raised by Stifel Nicolaus from GBX 49 ($0.64) to GBX 63 ($0.82) in a research note published on Wednesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Peel Hunt reaffirmed an under review rating on shares of Sinclair Pharma PLC in a report on Friday, May 20th. Jefferies Group decreased their price objective on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a buy rating for the company in a report on Wednesday, June 15th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Sinclair Pharma PLC currently has a consensus rating of Buy and an average target price of GBX 57 ($0.74).

Shares of Sinclair Pharma PLC (LON:SPH) opened at 27.00 on Wednesday. Sinclair Pharma PLC has a one year low of GBX 26.25 and a one year high of GBX 61.33. The stock’s market cap is GBX 134.19 million. The stock’s 50 day moving average price is GBX 29.92 and its 200 day moving average price is GBX 32.76.

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.